SENS Back Testing The 382 Fib Watching To Act As Support
The thing about
SENS
is that it's been a company crushing it in 2021. When it was first discussed this year it was still trading below $1. Despite recent volatility, it's up significantly year-to-date. I think volume remains steady but definitely on the lower end of the range. But good data from the last presentation on its PROMISE study seems to have sparked more attention.
"The data evaluating the safety and accuracy of the next generation Eversense system was presented by Satish Garg , MD, Professor of Medicine at the Barbara Davis Center of the University of Colorado, Denver , and the PROMISE study group Principal Investigator (PI). The Company presented previously released information demonstrating performance matching that of the current 90-day sensor available in the United States , with reduced calibration, down to one per day, with duration extended to 180 days. Accuracy measurements discussed in the oral presentation include a mean absolute relative difference (MARD) of 9.1% for the primary sensor and confirmed hypoglycemia alert detection rates at 60 mg/dL of 87% and at 70 mg/dL of 93%. For the subset of 43 modified sensors (referred to as the SBA sensor), the MARD was 8.5% and the confirmed hypo alert detection rates at 60 mg/dL and 70 mg/dL were 90% and 94%, respectively."
Another area of potential support/resistance is just below the 382 fib line (in yellow), which has held so far this week. It was resistance a few weeks back. With SENS failing almost right at the 236 Fib line, technical traders are liking monitoring these levels closely.
Latest on SENS: Best Penny Stocks to Buy Right Now? 7 Small-Caps For Your Morning List
SENS
is that it's been a company crushing it in 2021. When it was first discussed this year it was still trading below $1. Despite recent volatility, it's up significantly year-to-date. I think volume remains steady but definitely on the lower end of the range. But good data from the last presentation on its PROMISE study seems to have sparked more attention. "The data evaluating the safety and accuracy of the next generation Eversense system was presented by Satish Garg , MD, Professor of Medicine at the Barbara Davis Center of the University of Colorado, Denver , and the PROMISE study group Principal Investigator (PI). The Company presented previously released information demonstrating performance matching that of the current 90-day sensor available in the United States , with reduced calibration, down to one per day, with duration extended to 180 days. Accuracy measurements discussed in the oral presentation include a mean absolute relative difference (MARD) of 9.1% for the primary sensor and confirmed hypoglycemia alert detection rates at 60 mg/dL of 87% and at 70 mg/dL of 93%. For the subset of 43 modified sensors (referred to as the SBA sensor), the MARD was 8.5% and the confirmed hypo alert detection rates at 60 mg/dL and 70 mg/dL were 90% and 94%, respectively."
Another area of potential support/resistance is just below the 382 fib line (in yellow), which has held so far this week. It was resistance a few weeks back. With SENS failing almost right at the 236 Fib line, technical traders are liking monitoring these levels closely.
Latest on SENS: Best Penny Stocks to Buy Right Now? 7 Small-Caps For Your Morning List
